77 related articles for article (PubMed ID: 6013064)
21. A novel hydroxamic acid compound, BMD188, demonstrates anti-prostate cancer effects by inducing apoptosis. II: In vivo efficacy and pharmacokinetic studies.
Li L; Zhu Z; Joshi B; Zhang C; Johnson CR; Marnett LJ; Honn KV; Crissman JD; Porter AT; Tang DG
Anticancer Res; 1999; 19(1A):61-9. PubMed ID: 10226525
[TBL] [Abstract][Full Text] [Related]
22. Boric acid inhibits embryonic histone deacetylases: a suggested mechanism to explain boric acid-related teratogenicity.
Di Renzo F; Cappelletti G; Broccia ML; Giavini E; Menegola E
Toxicol Appl Pharmacol; 2007 Apr; 220(2):178-85. PubMed ID: 17320131
[TBL] [Abstract][Full Text] [Related]
23. Adrenergic activity of methyl-alpha-(p-nitrophenyl)-beta-(1-pyrrolidinyl) propionate.
Riera de Narvaez AJ; Vicuña Fernández N
J Pharm Belg; 1993; 48(5):357-64. PubMed ID: 8120788
[TBL] [Abstract][Full Text] [Related]
24. [Toxicological and pharmacological studies on a new drug: pirfibrate (EL-466) (author's transl)].
de la Fuente R; Santos M
Arch Farmacol Toxicol; 1980 Dec; 6(3):255-64. PubMed ID: 7305456
[No Abstract] [Full Text] [Related]
25. Inhibition of histone deacetylase activity by trichostatin A modulates gene expression during mouse embryogenesis without apparent toxicity.
Nervi C; Borello U; Fazi F; Buffa V; Pelicci PG; Cossu G
Cancer Res; 2001 Feb; 61(4):1247-9. PubMed ID: 11245412
[TBL] [Abstract][Full Text] [Related]
26. Metabolism distribution and excretion of a matrix metalloproteinase-13 inhibitor, 4-[4-(4-fluorophenoxy)-benzenesulfonylamino]tetrahydropyran-4-carboxylic acid hydroxyamide (CP-544439), in rats and dogs: assessment of the metabolic profile of CP-544439 in plasma and urine of humans.
Dalvie D; Cosker T; Boyden T; Zhou S; Schroeder C; Potchoiba MJ
Drug Metab Dispos; 2008 Sep; 36(9):1869-83. PubMed ID: 18566038
[TBL] [Abstract][Full Text] [Related]
27. Hydroxamic acid: a potential human teratogen that could be recommended to treat ureaplasma.
Holmes LB
Teratology; 1996 Apr; 53(4):227-9. PubMed ID: 8864163
[TBL] [Abstract][Full Text] [Related]
28. Inhibitory effect of new quinolones on GABA(A) receptor-mediated response and its potentiation with felbinac in Xenopus oocytes injected with mouse-brain mRNA: correlation with convulsive potency in vivo.
Kawakami J; Yamamoto K; Asanuma A; Yanagisawa K; Sawada Y; Iga T
Toxicol Appl Pharmacol; 1997 Aug; 145(2):246-54. PubMed ID: 9266796
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of histone deacetylase activity on specific embryonic tissues as a new mechanism for teratogenicity.
Menegola E; Di Renzo F; Broccia ML; Prudenziati M; Minucci S; Massa V; Giavini E
Birth Defects Res B Dev Reprod Toxicol; 2005 Oct; 74(5):392-8. PubMed ID: 16193500
[TBL] [Abstract][Full Text] [Related]
30. [Trial of P-butoxyphenylacethydroxamic acid in otorhinolaryngologic clinic].
Plisnier H
Brux Med; 1969 Dec; 49(12):813-5. PubMed ID: 5405286
[No Abstract] [Full Text] [Related]
31. Structure-activity relationship for two lipoxygenase inhibitors and their potential for inducing nephrotic syndrome.
Morley TJ; Evans GO; Goodwin DA; Read NG; Hodgson ST; Hawksworth GM
Toxicol Appl Pharmacol; 1997 Oct; 146(2):299-308. PubMed ID: 9344898
[TBL] [Abstract][Full Text] [Related]
32. Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats.
Renkiewicz R; Qiu L; Lesch C; Sun X; Devalaraja R; Cody T; Kaldjian E; Welgus H; Baragi V
Arthritis Rheum; 2003 Jun; 48(6):1742-9. PubMed ID: 12794843
[TBL] [Abstract][Full Text] [Related]
33. Changes in brain interleukin-1beta following the coadministration of norfloxacin with biphenylacetic acid in rats.
Zhang LR; Li XT; Tang WL; Wang YM; Cheng NN; Chen BY
Eur J Pharmacol; 2006 Aug; 543(1-3):21-6. PubMed ID: 16824509
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
Beebe JS; Jani JP; Knauth E; Goodwin P; Higdon C; Rossi AM; Emerson E; Finkelstein M; Floyd E; Harriman S; Atherton J; Hillerman S; Soderstrom C; Kou K; Gant T; Noe MC; Foster B; Rastinejad F; Marx MA; Schaeffer T; Whalen PM; Roberts WG
Cancer Res; 2003 Nov; 63(21):7301-9. PubMed ID: 14612527
[TBL] [Abstract][Full Text] [Related]
35. [Pharmacological studies on decanohydroxamic acid. IV. Subacute oral toxicity on rats].
Kitagawa H; Yoshida S; Abe M; Fukuda Y
Yakugaku Zasshi; 1965 Nov; 85(11):1012-6. PubMed ID: 5893830
[No Abstract] [Full Text] [Related]
36. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
[TBL] [Abstract][Full Text] [Related]
37. [A study on cell malignant transformation caused by dihydroxyglyoxime].
Shen J; Jiang Y; Zhang Z
Zhonghua Yu Fang Yi Xue Za Zhi; 1997 Nov; 31(6):346-8. PubMed ID: 9863068
[TBL] [Abstract][Full Text] [Related]
38. Polymer analogs of 3-chloro-4-benzyloxyphenylacetic acid and their pharmacological activity.
Hrabák F; Grimová J; Maturová E; Kuchar M
J Biomed Mater Res; 1983 Jan; 17(1):179-84. PubMed ID: 6826573
[TBL] [Abstract][Full Text] [Related]
39. Role of matrix metalloproteinases in apoptosis after transient focal cerebral ischemia in rats and mice.
Copin JC; Goodyear MC; Gidday JM; Shah AR; Gascon E; Dayer A; Morel DM; Gasche Y
Eur J Neurosci; 2005 Oct; 22(7):1597-608. PubMed ID: 16197500
[TBL] [Abstract][Full Text] [Related]
40. Antiteratogenic effects of tumor inhibitors, caffeine, antipain, and retinoic acid in mice.
Nomura T; Enomoto T; Shibata K; Kanzaki T; Tanaka H; Hata S; Kimura S; Kusafuka T; Sobue K; Miyamoto S
Cancer Res; 1983 Nov; 43(11):5156-62. PubMed ID: 6413055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
